SLC5A2 and chronic kidney disease: Meta-analysis performed by the Nuffield Department of Population Health Renal Studies Group and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium analyzing the nephroprotective effect of SGLT2i in patients with T2D and established CKD randomized to the CREDENCE, SCORED, DAPA-CKD, and EMPA-KIDNEY trials indicated the clear renal benefit (relative risk—RR 0.60 [95% CI 0.53–0.69]), with only one drug (sotagliflozin) and study (SCORED) demonstrating lack of nephroprotective efficacy [41].